<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116804</url>
  </required_header>
  <id_info>
    <org_study_id>2010/115</org_study_id>
    <nct_id>NCT01116804</nct_id>
  </id_info>
  <brief_title>Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have
      several shortcomings. One important shortcoming is the time delay between successful
      treatment and radiological confirmation of this response. Often it takes several months for
      anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI
      (shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of
      Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early
      indicator of response. This &quot;early&quot; information might help to tailor treatment. For instance,
      if no response is induced, an early switch in therapy can be planned.

      The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and the
      experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with
      inoperable primary liver cancer is treated (radionuclide therapy, biologicals).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer</measure>
    <time_frame>6 months after start of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Primary Liver Cancer</condition>
  <arm_group>
    <arm_group_label>inoperable liver cancer patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI of the liver before start of treatment</intervention_name>
    <description>MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)</description>
    <arm_group_label>inoperable liver cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI after treatment</intervention_name>
    <description>MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)</description>
    <arm_group_label>inoperable liver cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET-scan before treatment start</intervention_name>
    <description>PET-scan with 2 tracers is performed before treatment start</description>
    <arm_group_label>inoperable liver cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET scan after treatment</intervention_name>
    <description>PET-scan with 2 tracers is repeated 4 weeks following start of treatment</description>
    <arm_group_label>inoperable liver cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Male and female are eligible

             -&gt;18years of age.No upper age limit.

          -  not pregnant or breastfeeding

          -  capable of understanding the study goals and protocol and to sign the informed
             consent.

          -  Patients are diagnosed with primary liver cancer and referred for treatment with
             biologicals such as Sorafenib or treatment with radionuclides.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bieke Lambert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bieke Lambert, MD</last_name>
    <email>bieke.lambert@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bieke Lambert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>H. Van Vlierberghe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R. Troisi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>L. Defreyne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>P. Smeets, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>website University Hospital Ghent</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

